(Las Vegas Nevada United States), DelveInsight’s, “Food Allergy- Pipeline Insight, 2023” report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in the Food Allergy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Food Allergy Pipeline Report
-
Over 30+ Companies and 35+ Pipeline Drugs for Food Allergy are in various stages of development, and their anticipated acceptance in the Food Allergy market would significantly increase market revenue.
-
Leading Food Allergy companies developing novel drug candidates to improve the Food Allergy treatment landscape include Merck & Co, DBV technologies, Novartis Pharmaceuticals, Astrazeneca, and many others
-
Promising Food Allergy pipeline therapies in various stages of development include ARO-AAT, Omalizumab: and many others.
Food Allergy Overview
A food allergy occurs when the body’s immune system sees a certain food as harmful and reacts by causing symptoms. This is an allergic reaction. Foods that cause allergic reactions are allergens. The results of skin prick tests (SPT), IgE total and specific antibodies, and patient histories are not predictive of true food allergy, as they are not able to establish the causal and temporal relationship between the intake of the suspect food and the hypersensitivity reaction. The negative predictive accuracy of a skin prick test weal of < 3mm greater than the negative control is high, usually > 95%, and is strong evidence that the food may be consumed without severe, immediate food-allergic reactions. A positive SPT, even a wheal of 3 mm or more, may be clinically irrelevant, as the patient may tolerate the ingested food. SPTs may also remain positive after the development of tolerance to the specific food. The foods to which an individual is allergic should be avoided, as therapeutic intervention (tertiary prevention) in patients with food allergy. It must strike a precautionary equilibrium between the demands of prohibitive measures against allergy care and quality of life. Hypersensitivity reactions are often treated with medications. Epinephrine is the only medication that is effective for the treatment of anaphylaxis. Additional medications include H1 and H2 antihistamines, corticosteroids, and prostaglandin synthetase inhibitors.
Food Allergy Pipeline Analysis: Drug Profile
Viaskin Peanut: DBV technologies
Investigational Viaskin® Peanut therapeutic treatment is based on epicutaneous immunotherapy or EPIT™. This potential new class of immunotherapey is designed to work by delivering allergens to the immune system through intact skin using our proprietary Viaskin® technology. For those patients facing potentially life-threatening food allergies, this potential immunotherapy treatment aims to desensitize them to allergens by delivering compounds in small quantities into the outer layers of the skin. The investigational EPIT aims to target specific epidermal dendritic cells, called Langerhans cells. Pre-clinical research has shown that these cells capture antigens and migrate to the lymph node in order to activate the immune system.
Discover more about the emerging Food Allergy drugs @ Food Allergy Treatment Drugs
Food Allergy Pipeline Therapies and Key Companies
-
Merck & Co: ARO-AAT, Omalizumab
-
DBV technologies : Omalizuma
And many others
Food Allergy Pipeline Therapeutics Assessment
Phases
DelveInsight’s Report covers around 10+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued and inactive candidates
Food Allergies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Inhalation
-
Inhalation/Intravenous/Oral
-
Intranasal
-
Intravenous
-
Intravenous/ Subcutaneous
-
NA
-
Oral
-
Oral/intranasal/subcutaneous
-
Parenteral
-
Subcutaneous
Molecule Type
Products have been categorized under various Molecule types such as
-
Antibody
-
Antisense oligonucleotides
-
Immunotherapy
-
Monoclonal antibody
-
Peptides
-
Protein
-
Recombinant protein
-
Small molecule
-
Stem Cell
-
Vaccine
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Scope of the Food Allergy Pipeline Report
-
Coverage: Global
-
Key Food Allergy Companies: Arrowhead Pharmaceuticals and others.
-
Key Food Allergy Pipeline Therapies AR0-AAT, and many others
Find out more about the Food Allergy treatment options in development @ Food Allergy Clinical Trials
Table of Contents
1. Food Allergy Introduction
2. Food Allergy Executive Summary
3. Food Allergy Overview
4. Food Allergy Pipeline Therapeutics
5. Food Allergy Late-Stage Products (Phase III)
6. Food Allergy Mid-Stage Products (Phase II)
7. Food Allergy Early Stage Products (Phase I/II)
8. Food Allergy Preclinical Stage Products
9. Food Allergy Discovery Stage Products
10. Food Allergy Therapeutic Assessment
11. Food Allergy Inactive Products
12. Food Allergy Collaborations Assessment- Licensing / Partnering / Funding
13. Food Allergy Unmet Needs
14. Food Allergy Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services